Sei Investments Co. Has $15.32 Million Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Sei Investments Co. boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 3.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,061,967 shares of the company’s stock after buying an additional 37,145 shares during the quarter. Sei Investments Co. owned approximately 0.21% of Elanco Animal Health worth $15,324,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Janney Montgomery Scott LLC bought a new stake in Elanco Animal Health in the 4th quarter valued at $913,000. UBS Group AG increased its holdings in shares of Elanco Animal Health by 63.8% in the fourth quarter. UBS Group AG now owns 1,117,196 shares of the company’s stock valued at $16,646,000 after purchasing an additional 435,291 shares during the last quarter. Commerce Bank raised its position in shares of Elanco Animal Health by 3.8% in the fourth quarter. Commerce Bank now owns 33,665 shares of the company’s stock valued at $502,000 after purchasing an additional 1,223 shares during the period. Hsbc Holdings PLC lifted its stake in shares of Elanco Animal Health by 546.6% during the 4th quarter. Hsbc Holdings PLC now owns 208,977 shares of the company’s stock worth $3,129,000 after buying an additional 176,656 shares during the last quarter. Finally, TD Asset Management Inc boosted its holdings in shares of Elanco Animal Health by 20.4% during the 4th quarter. TD Asset Management Inc now owns 331,585 shares of the company’s stock worth $4,941,000 after buying an additional 56,266 shares during the period. Institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on ELAN shares. Barclays raised their price objective on shares of Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Piper Sandler decreased their price objective on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Elanco Animal Health currently has an average rating of “Hold” and an average price target of $17.43.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $13.72 on Friday. The company has a market cap of $6.78 billion, a price-to-earnings ratio of -5.18, a PEG ratio of 1.33 and a beta of 1.40. Elanco Animal Health Incorporated has a fifty-two week low of $8.52 and a fifty-two week high of $18.80. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. The stock has a fifty day moving average price of $14.02 and a 200-day moving average price of $15.09.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The business had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter in the prior year, the business posted $0.18 earnings per share. Elanco Animal Health’s revenue was up 12.0% compared to the same quarter last year. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 100,000 shares of the business’s stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the purchase, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at $1,886,450. The acquisition was disclosed in a filing with the SEC, which is available at this link. In related news, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were bought at an average cost of $14.85 per share, with a total value of $51,975.00. Following the acquisition, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the purchase, the chief executive officer now owns 145,000 shares in the company, valued at $1,886,450. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.